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Impaired daily activitiesIntroduction: Obesity and type 2 diabetes mellitus have reached epidemic proportions worldwide.
Abnormal sleep has been linked to both incident and prevalent obesity and type 2 diabetes. We aimed
to characterize abnormal sleep patterns [ASP’s] in patients with obesity, type 2 diabetes, or both.
Subjects: The study included 92 subjects divided into four groups: Group 1, 23 obese patients (BMI >
30) with type 2 diabetes mellitus; Group 2, 23 non-obese diabetic patients; group 3, 23 obese subjects
without diabetes; group 4, 23 matched healthy control subjects. Methods: Waist circumference and
BMI [body mass index] estimation, fasting and post challenge plasma glucose ‘‘groups 2 & 4”, HOMA-
IR [Homeostatic model assessment- Insulin resistance] estimation, and finally evaluation for ASP’s using
a CDC [Centers for Disease Control and prevention] validated questionnaire. Results: Post-prandial glucose
and BMI significantly predicted Sleep latency and sleep hours at night respectively. Both group 1 and 3
compared to group 4 showed higher prevalence of: Insomnia [p < .01], snoring [p < .01], fragmented sleep
[p < .05], excessive day time sleepiness [p < .001], and daytime dysfunction [p < .001]. Group 2 compared
to group 4 showed higher prevalence of: Insomnia, snoring, fragmented sleep, and finally, daytime dys-
function [All p < .01]. Group 1 compared to groups 3 and 4 had significantly less hours of sleep at night [p
< .01]. Group 1 compared to group 2 showed higher prevalence of: Insomnia, fragmented sleep, excessive
day time sleepiness, and daytime dysfunction [All p < .05]. Finally, group 3 compared to group 2 showed
higher prevalence of: Excessive day time sleepiness, and daytime dysfunction [p < .01]. Conclusion: The
combination of obesity and diabetes mellitus is associated with poor quality and quantity of sleep with
resultant significant daytime dysfunction. Glycemic, and adiposity measures predicted sleep latency and
hours.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes Mellitus (DM) is a global emergency and epidemic.
Current estimates of world population with diabetes ranges
between 415 and 422 million according to IDF (International Dia-
betes Federation) and WHO (World Health Organization) respec-
tively, and expected to reach 642 million by the year 2040.1,2
Obesity is a major global health challenge, the prevalence has
been increasing in the past 30 years, so that in 2013, it was esti-
mated that worldwide 37%, and 38% of adult men and womenrespectively, and 24%, and 23% of boys and girls respectively are
either overweight or obese.3
Sleep disorders and short sleep duration are an emerging public
health issue. According to the National Heart, Lung, and Blood
Institute of the National Institutes of Health, around 50 to 70 mil-
lion US (United States) adults suffer from a sleep disorder or report
short sleep duration. The prevalence of insomnia symptoms at any
given time ranges from 30% to 45%, however, only 6% of people
with insomnia receive a diagnosis. Sleep apnea has an estimated
prevalence of 27% to 34% among men and 9% to 28% among
women, 30 to 70 years of age. Around 27.5% to 29.1% of American
adults reported short sleep duration.4
Meta-analyses of cross-sectional and prospective studies have
shown that short sleep duration is linked to both prevalent and
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respectively.5–8
Possible mechanisms to explain the association between sleep
deprivation and sleep disordered breathing and the increased like-
lihood of obesity and diabetes include.
Increased ghrelin, NPY (Neuropeptide Y), orexin-A, and endo-
cannabinoids, decreased leptin, GLP-1 (Glucagon like peptide-1),
and melatonin combined lead to increased appetite, Increased
desire to eat high caloric food, increased both hedonic and home-
ostatic eating, increased adipose tissue accumulation and
decreased gastric fullness scores, ultimately leading to Increased
caloric intake by a range from 297 to 559 kcal per day. This is
aggravated by decreased physical activity, doubled sedentary
activity and TV watching leading to obesity. Genetic correlation
between increased levels of EDS and increased measures for adi-
posity traits; BMI, and WC was recently reported.9–16
Short sleep, sleep fragmentation, and OSA were shown to
induce insulin resistance through: prolonged nocturnal GH
(Growth Hormone) secretion, increased afternoon concentrations
of cortisol, increased early morning NE (Nor-Epinephrine) concen-
trations, Increased release of free fatty acids, obesity, Low grade
inflammation, Decreased adiponectin, decreased nocturnal mela-
tonin affecting both insulin secretion and action. Insulin resistance
along with a decrease in cerebral glucose utilization eventually
lead to diabetes.17–24
The aim of the present study was to characterize abnormal
sleep patterns [ASP’s] across the continuum of type 2 diabetes
and obesity and their relation to insulin resistance.2. Subjects
The study included 92 subjects divided into four groups: Group
1, 23 patients who are obese (BMI > 30) and suffering from type 2
diabetes mellitus; Group 2, 23 patients who are Diabetics but non-
obese; group 3, 23 subjects who are obese with normal glucose tol-
erance; group 4, 23 healthy control subjects who are non-obese
with normal glucose tolerance. We excluded from the study sub-
jects who are: under 18 years of age, or with known liver, cardiac,
pulmonary, and renal disorders. Alexandria Faculty of Medicine
Ethical committee approved the protocol of the study, and all study
participants provided a written informed consent after being
explained the nature and aim of the study.3. Methods
All participants were subjected to: WC in centimeters (waist
circumference) and BMI (Body mass index) estimation [Body
weight in Kg/Height in m2], fasting and post challenge plasma glu-
cose [with 75 grams of oral glucose load, FBG < 100 mg/dl and post
challenge glucose < 140 mg/dl were considered normal glucose
tolerance excluding diabetes] ‘‘groups 2 & 4”, HOMA-IR (Homeo-
static model assessment-Insulin resistance) estimation [Fasting
plasma glucose mg/dl  fasting insulin mIU/L/ 405], and finally
evaluated for ASP’s using NHANES (National Health and Nutrition
Examination Survey) sleep questionnaire that included items from
2 validated tools: Sleep Heart Health Study Sleep Habits Question-
naire, Functional Outcomes of Sleep Questionnaire.25–30
The questionnaire is divided into 3 parts, the first is about sleep-
ing habits in 7 questions, the second is about sleeping habits in the
past month in 9 questions, and finally the third is about difficulty
carrying out certain activities because of being too sleepy in 8
questions. In our presentation of the results, we referred to the 3
different parts of the NHANES questionnaire as questionnaires I,
II, and III.11The following sleep related parameters and ASP’s in the studied
groups were assessed using the following corresponding questions
highlighted in quotation marks:
Total sleep time: ‘‘Number of hours of sleep at night on
weekdays”.
Snoring as a surrogate marker of SDB (Sleep disordered breath-
ing) or OSA (Obstructive sleep apnea): ‘‘How often do you snore
while sleeping”.
Insomnia defined as difficulty initiating or maintaining
sleep: ‘‘Time taken to fall asleep at bedtime”, i.e. sleep latency per-
iod, ‘‘Having trouble falling asleep”, ‘‘Having trouble getting back to
sleep after waking up during night”, ‘‘Waking up too early in the
morning”.
Sleep abnormalities that may lead to sleep fragmentation:
‘‘Having nocturia”, ‘‘Having leg jerks while trying to sleep”, ‘‘Having
leg cramps while trying to sleep”.
Excessive day time sleepiness ‘‘EDS: ‘‘Feeling excessively or
overly sleepy during the day”, ‘‘Not getting enough sleep”.
Daytime dysfunction or impairment: ‘‘Having difficulty con-
centrating because of feeling sleepy”, ‘‘Having difficulty remem-
bering because of feeling sleepy”, ‘‘Having difficulty working on a
hobby”, ‘‘Having difficulty getting things done”, ‘‘Having difficulty
performing employed work because of feeling sleepy”, ‘‘Having dif-
ficulty maintaining a telephone conversation because of feeling
sleepy”.3.1. Statistical methods
Data were analyzed using IBM SPSS software package version
20.0, Armonk, NY: IBM Corp. Comparison between different groups
regarding categorical variables was tested using Chi-square test.
When more than 20% of the cells have expected count less than
5, correction for chi-square was conducted using Monte Carlo cor-
rection. The distributions of quantitative variables were tested for
normality. For normally distributed data, comparison between the
different studied groups were analyzed using F-test (ANOVA),
while for abnormally distributed data Kruskal Wallis test was used.
Significance of the obtained results was judged at the 5% level.4. Results
The four studied groups were matched for age, however, BMI,
WC, FBG, 2HPPG, and HOMA-IR showed significant intergroup dif-
ferences as expected based on selection criteria for each group
[Table 1].
In our study, diabetic non-obese individuals ‘‘group 2” com-
pared to non-diabetics non-obese ‘‘group 4” showed significantly
higher prevalence of:
Insomnia in terms of more time to fall asleep, and waking up
too early in the morning. Snoring; a surrogate marker of sleep dis-
ordered breathing. More fragmented sleep in terms of having leg
cramps while trying to sleep. Finally, more daytime dysfunction
in terms of having difficulty concentrating, remembering, working
on a hoppy, and maintaining a telephone conversation because of
feeling sleepy [Tables 2 and 3] [Figs. 1 and 2].
Also, both diabetic obese individuals ‘‘group 1” and obese non-
diabetic individuals ‘‘group 3” compared to non-diabetics non-
obese ‘‘group 4” showed significantly higher prevalence of:
Insomnia in terms of more time to fall asleep, having trouble
falling asleep, having trouble getting back to sleep after waking
up during night, and waking up too early in the morning. Snoring;
a surrogate marker of sleep disordered breathing. More frag-
mented sleep in terms of having nocturia, leg jerks, and leg cramps
while trying to sleep. Excessive day time sleepiness in terms of not
getting enough sleep, and feeling excessively or overly sleepy
Table 1
Clinical, anthropometric, and biochemical characteristics of the 4 studied groups.









Age (years) 48.13 ± 7.37 48.35 ± 6.60 45.96 ± 11.55 45.48 ± 10.91 .637
BMI (kg/m2) 37.76 ± 5.87 27.25 ± 2.85 33.27 ± 2.63 25.62 ± 2.78 <.001*
p1 < .001*, p2 = .001*, p3 < .001*, p4 < .001*, p5 = .469, p6 < .001*
WC (cm) 119.96 ± 9.73 104.43 ± 15.43 103.39 ± 10.43 83.39 ± 12.04 <.001*
p1 < .001*, p2 < .001*, p3 < .001*, p4 = .991, p5 < .001*, p6 < .001*
FBG (mg/dl) 239.78 ± 95.02 240.96 ± 120.10 84.35 ± 8.63 78.43 ± 8.39 <.001*
p1 = .860, p2 < .001*, p3 < .001*, p4 < .001*, p5 < .001*, p6 = .017*
2HPPG (mg/dl) 309.13 ± 112.52 323.57 ± 97.48 101.78 ± 17.16 86.52 ± 12.57 <.001*
p1 = .668, p2 < .001*, p3 < .001*, p4 < .001*, p5 < .001*, p6 = .001*
HOMA-IR 9.06 ± 6.76 9.07 ± 8.03 2.52 ± 1.66 1.64 ± 0.78 <.001*
p1 = .886, p2 < .001*, p3 < .001*, p4 < .001*, p5 < .001*, p6 = .063
BMI; Body mass index, WC; Waist circumference, FBG; Fasting blood glucose, 2HPPG; 2 hours post prandial glucose, HOMA-IR; Homeostatic model assessment-Insulin
resistance.
p1: p value for comparing between group 1 and group 2.
p2: p value for comparing between group 1 and group 3.
p3: p value for comparing between group1 and group 4.
p4: p value for comparing between group 2 and group 3.
p5: p value for comparing between group 2 and group 4.
p6: p value for comparing between group 3 and group 4.
Group 1 (Diabetic + Obese) BMI  30.
Group 2 (Diabetic + Non-obese) BMI < 30.
Group 3 ((Non-Diabetic) Normal glucose tolerance + Obese) BMI  30.
Group 4 ((Non-Diabetic) Normal glucose tolerance + Non-obese) BMI < 30.
* Statistically significant at p  .05.
Table 2
Comparison between the studied groups according to Questionnaire I.









Q1-Sleeping hours on week days [in hours] 6.13 ± 1.96 7.09 ± 1.35 7.17 ± 0.78 7.70 ± 0.93 .001*
p1 = .23, p2 = .003*, p3 < .001*, p4 = .712, p5 = .086, p6 = .056
Q2-Time taken to fall asleep at bedtime? [in hours] 0.77 ± 0.57 0.79 ± 0.55 0.51 ± 0.26 0.50 ± 0.25 <.001*
p1 = .816, p2 = .085, p3 = .001*, p4 = .041*, p5 < .001*, p6 < .001*
Q3-How often did you snore while you were sleeping? 13(56.5)¥ 10(43.5) 2(8.6) 0(0) MCp < .001*
p1 = .220, p2 = .005*, p3 < .001*, p4 = .035*, p5 = .002*, p6 = .008*
Q4-Having nocturia 22(95.7) y 15(65.2) 17(73.9) 8(34.8) <.001*
p1 = .022*, p2 = .096, p3 < .001*, p4 = .749, p5 = .076, p6 = .017*
p1: p value for comparing between group 1 and group 2.
p2: p value for comparing between group 1 and group 3.
p3: p value for comparing between group1 and group 4.
p4: p value for comparing between group 2 and group 3.
p5: p value for comparing between group 2 and group 4.
p6: p value for comparing between group 3 and group 4.
Group 1 (Diabetic + Obese) BMI  30.
Group 2 (Diabetic + Non-obese) BMI < 30.
Group 3 ((Non-Diabetic) Normal glucose tolerance + Obese) BMI  30.
Group 4 ((Non-Diabetic) Normal glucose tolerance + Non-obese) BMI < 30.
* Statistically significant at p  .05.
¥ Values are expressed as numbers and percent of subjects who snored while sleeping occasionally or frequently.
y Values are expressed as numbers and percent of subjects suffering from nocturia.
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ing difficulty concentrating, remembering, performing employed
work, and maintaining a telephone conversation because of feeling
sleepy [Tables 2 and 3] [Figs. 1 and 2].
Diabetic obese individuals ‘‘group 1” compared to obese non-
diabetic individuals ‘‘group 3” and non-diabetics non-obese ‘‘group
4” showed significantly shorter sleep duration in terms of having
significantly less hours of sleep at night on weekdays [Table 2]
[Fig. 1].
Diabetic obese individuals ‘‘group 1” compared to diabetic non-
obese individuals ‘‘group 2” showed significantly higher preva-
lence of:Insomnia in terms of having trouble falling asleep. More frag-
mented sleep in terms of having nocturia. Excessive day time
sleepiness in terms of not getting enough sleep, and feeling exces-
sively or overly sleepy during the day. Lastly, more daytime dys-
function in terms of having difficulty maintaining a telephone
conversation because of feeling sleepy [Tables 2 and 3] [Fig. 2].
Finally, obese non-diabetic individuals ‘‘group 3” compared to
diabetic non-obese individuals ‘‘group 2” showed significantly
higher prevalence of:
Excessive day time sleepiness in terms of not getting enough
sleep, and feeling excessively or overly sleepy during the day. More
daytime dysfunction in terms of having difficulty getting things
Table 3
Comparison between the studied groups according to Questionnaires II, III.
In the past month Group (n = 23) Group 2(n = 23) Group 3(n = 23) Group 4(n = 23) p
N (%) N (%) N (%) N (%)
Q1-Trouble falling asleep 18(78.3) 7(30.4) 16(69.6) 1(4.3) <.001*
p1 = .001*, p2 = .502, p3 = <.001*, p4 = .008*, p5 = .04*, p6 = <.001*
Q2-Waking up during the night with trouble getting back to sleep 15(65.2) 13(56.5) 15(65.2) 3(13.2) .001*
p1 = .546, p2 = 1.000, p3 = <.001*, p4 = .546, p5 = .002*, p6 = <.001*
Q3-Waking up too early in the morning and unable to get back to sleep 17(73.9) 16(69.6) 18(78.3) 1(4.3) <.001*
p1 = .743, p2 = .730, p3 = <.001*, p4 = .502, p5 = <.001*, p6 = <.001*
Q4-Feeling unrested during the day, no matter how many hours of sleep 18(78.3) 15(65.2) 20(87) 7(30.4) <.001*
p1 = .326, p2 = .699, p3 = .001*, p4 = .084, p5 = .018*, p6 = <.001*
Q5-feeling excessively or overly sleepy during the day 20(87) 12(52.2) 21(91.3) 7(30.4) <.001*
p1 = .010*, p2 = 1.000, p3 = <.001*, p4 = .003*, p5 = .134, p6 = <.001*
Q6-Not getting enough sleep 18(78.3) 10(43.5) 19(82.6) 4(17.4) <.001*
p1 = .016*, p2 = 1.000, p3 = <.001*, p4 = .006*, p5 = .055, p6 = <.001*
Q8- Having leg jerks while trying to sleep 14(60.9) 8(34.8) 10(43.5) 3(13.2) .009*
p1 = .077, p2 = .238, p3 = .001*, p4 = .546, p5 = .084, p6 = .022*
Q9-Having leg cramps while trying to sleep 19(82.6) 14(60.9) 16(69.6) 5(21.7) <.001*
p1 = .102, p2 = .300, p3 = <.001*, p4 = .536, p5 = .007*, p6 = .001*
Q1- Having Difficulty Concentrating because you feel sleepy 18(78.3) 14(60.9) 19(82.6) 4(17.4) <.001*
p1 = .200, p2 = 1.000, p3 = <.001*, p4 = .102, p5 = .003*, p6 = <.001*
Q2- Having difficulty remembering because you are sleepy 22(95.7) 20(87) 22(95.7) 7(30.4) <.001*
p1 = .608, p2 = 1.000, p3 = <.001*, p4 = .608, p5 = <.001*, p6 = <.001*
Q4- having difficulty working on a hobby because you are sleepy 9(39.1) 5(21.7) 18(78.3) 12(52.2) .001*
p1 = .200, p2 = .007*, p3 = .375, p4 = <.001*, p5 = .032*, p6 = .063
Q4- having difficulty getting things done because you are sleepy 17(73.9) 14(60.9) 21(91.3) 13(56.5) .043*
p1 = .345, p2 = .243, p3 = .216, p4 = .016*, p5 = .765, p6 = .007*
Q7- having difficulty performing employed work because you are sleepy 17(73.9) 12(52.2) 17(73.9) 6(26.1) .002*
p1 = .127, p2 = 1.000, p3 = .001*, p4 = .127, p5 = .070, p6 = .001*
Q8- having difficulty maintain a telephone conversation because you are sleepy 15(65.2) 5(21.7) 12(52.2) 0(0) <.001*
p1 = .003*, p2 = .369, p3 = <.001*, p4 = .032*, p5 = .049*, p6 = <.001*
p1: p value for comparing between group 1 and group 2.
p2: p value for comparing between group 1 and group 3.
p3: p value for comparing between group1 and group 4.
p4: p value for comparing between group 2 and group 3.
p5: p value for comparing between group 2 and group 4.
p6: p value for comparing between group 3 and group 4.
Group 1 (Diabetic + Obese) BMI  30.
Group 2 (Diabetic + Non-obese) BMI < 30.
Group 3 ((Non-Diabetic) Normal glucose tolerance + Obese) BMI  30.
Group 4 ((Non-Diabetic) Normal glucose tolerance + Non-obese) BMI < 30.
* Statistically significant at p  .05.
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tion because of feeling sleepy [Table 3] [Fig. 2].
In the whole study group, time to fall asleep or sleep latency
period (LP) was significantly positively associated with FBG,
2HPPG, HOMA, and WC, while number of sleep hours at night were
significantly negatively associated with WC and BMI. Using a step-
wise regression model, only 2HPPG and BMI significantly predicted
sleep latency period (LP) and number of sleep hours respectively
[Tables 4 and 5].5. Discussion
The aim of the present study was to evaluate the prevalence of
abnormal sleep patterns [ASPs] across the continuum of type 2 dia-
betes and obesity and their relation to insulin resistance. Our
results showed a high prevalence of ASP’s in our cohort of diabet-
ics, obese, or both combined in terms of Insomnia, snoring as sur-
rogate marker of sleep disordered breathing, sleep abnormalities
that may lead to sleep fragmentation [nocturia, leg jerks and leg
cramps], excessive day time sleepiness, and daytime dysfunction.
Sleep latency period correlated significantly with insulin resistanceand glycemic parameters while number of sleep hours correlated
significantly with anthropometric measures of adiposity.
In a recent study by Plantinga et al. of self-reported sleep prob-
lems in 9848 adults (aged 20 y) participating in the NHANES
2005 through 2008 where Sleep problem information was elicited
via the same questionnaire used in our study, Diabetes was associ-
ated with increased odds of inadequate sleep, frequent daytime
sleepiness, restless legs symptoms, sleep apnea, and nocturia.
BMI partly explained this association. Waist circumference was
associated with sleep apnea with OR (Odds ratio), 1.03 per 1-cm
increase. Apnea, leg symptoms, daytime sleepiness, and nocturia
showed greater odds with increasing severity of diabetes in a sig-
nificant, graded fashion. Diabetes duration was significantly associ-
ated with the same problems; risk increased 20% to 30% per 10
years since diagnosis.31
Similarly, a high prevalence of sleep abnormalities among
T2DM patients have been reported in the literature. Poor sleep
quality as assessed by Pittsburgh Sleep Quality Index (PSQI) ques-
tionnaire in 49%, Excessive daytime sleepiness assessed by
Epworth sleepiness score in 28.9 to 46%, and obstructive sleep
apnea assessed by polysomnography in 48.7% of patients with
T2DM.32–34
Fig. 1. Sleep latency period (Time to fall asleep) and sleep hours at night across the four studied groups.
Fig. 2. Responses of the four studied groups to questionnaire III about difficulty carrying out daily activities because of being too sleepy.
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Table 4
Correlation between sleeping hours and time to fall asleep with different parameters
in total sample.
Sleeping hours Time to fall asleep
FBG r 0.105 0.305*
p .319 .003*
2HPPG r 0.119 0.377*
p .259 <.001*
HOMA.IR r 0.126 0.271*
p .232 .009*
BMI r 0.393* 0.192
p <.001* .067
WC r 0.244* 0.292*
p .019* .005*
r: Pearson coefficient.
* Statistically significant at p  .05.
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and adiposity measures has also been reported. Among diabetics,
higher sleep fragmentation or the presence of insomnia assessed
using questionnaire and actigraphy was associated with 12.6 to
28.8 mg/dl higher fasting plasma glucose and 43 to 82% higher
HOMA respectively.35 Among subjects with metabolic syndrome,
Epworth sleepiness score showed significant associations with
both BMI, and FBG.34
ASPs are not only related to the presence of diabetes but can
also influence the micro- and macrovascular complications arising
due to diabetes. T2DM Subjects with short sleep had a higher risk
of developing diabetic neuropathy; DKD (Diabetic kidney disease)
[OR 1.3]; CVD (Cardiovascular disease) [OR 1.6); and PAD (Periph-
eral arterial disease) [OR 1.34). T2DM Subjects with insomnia had a
higher risk of developing CVD [OR 1.35], while those with exces-
sive daytime sleepiness had a higher risk of diabetic
neuropathy.36,37
The observed higher prevalence of abnormal sleep patterns in
obese, diabetics, or obese diabetics in our study may be interpreted
in two ways: poor sleep causing diabetes and obesity or diabetes
and obesity causing poor sleep.6. Evidence in favor of poor sleep causing diabetes and obesity
Two meta-analysis of prospective studies that assess the rela-
tionship between sleep quality and quantity and the incidence of
type 2 diabetes, including 10 studies each, with follow up duration
ranging from 2.5 to 32 years; showed that short sleep duration,
long sleep duration, difficulty in initiating sleep, and difficulty in
maintaining sleep were associated with a significantly increased
risk of developing type 2 diabetes.8,38
Li et al. recently reported, in a prospective trial with up to 10
years of follow-up, that women who reported having one, two,
three, and all four sleep conditions namely; sleeping difficulty,Table 5
Stepwise regression models for predictors of time to fall asleep and sleeping hours.
Dependent Variable: Time to fall asleep
B Beta
2HPPG 0.001 0.377
R = 0.377 R2 = 0.142 F = 14.939*, p < .001*
Dependent Variable: Sleeping hours
B Beta
BMI 0.092 0.39
R = 0.393 R2 = 0.155 F = 16.488*, p < .001*
* Statistically significant at p  .05.frequent snoring, sleep duration 6 h and sleep apnea, had one
and a half fold, twofold, threefold, and more than a fourfold
increased likelihood of type 2 diabetes, respectively.39
Two prospective studies aimed to assess regular snoring as a
risk factor for incident T2DM during 10 years of follow up. In
males, the combination of obesity and habitual snoring were inde-
pendently associated with the development of diabetes, however,
Habitual snoring without obesity was not a risk factor for the
development of diabetes.40 In females, both occasional snoring
and regular snoring were associated with risk of diabetes com-
pared to no snoring.41
In a recent meta-analysis of prospective studies examining the
association between sleep duration and risk of obesity, short sleep
duration increased OR for obesity, both in males and in females,
and both in short and long follow-up duration (>5 years and 5
years).6 This was confirmed in the most recent prospective study
examining the association between Night-time sleep duration
and the incidence of obesity, the OR of becoming obese was signif-
icantly higher in subjects with short sleep duration, at both 6-years
and 11-years follow-up.427. Evidence in favor of diabetes causing poor sleep
Diabetes was associated with both obstructive and central sleep
apnea, obesity present in up to 86% and diabetic neuropathy pre-
sent in up to half of diabetic patients mediate this association
respectively. In the Sleep Heart Health Study (SHHS), the associa-
tion between diabetes and OSA was largely dependent on obesity,
in the same study, autonomic neuropathy directly affects central
chemoreceptors and through impaired cardiovascular function
affects cardiac chemoreceptors, combined they may lead to a peri-
odic (Cheyne Stokes) breathing pattern.43,44
In a recent study, both macrovascular and microvascular dia-
betic complications, namely nephropathy and retinopathy, inde-
pendently predicted early awakening, short sleep, and long
sleep.17 In another study, diabetic peripheral neuropathy predicted
the presence of RLS, and poor sleep quality as assessed by PSQI was
related to the presence of RLS, and peripheral neuropathy.45
Nocturia, reported in Up to 80% of patients with type 2 diabetes
mellitus, is highly prevalent in patients with intrinsic sleep disor-
ders like insomnia, poor sleep quality, EDS, snoring, and OSA. indi-
viduals awakened by nocturia are more likely to report poor sleep
quality, and EDS.46,47
Nocturnal hypoglycemia characterized by a rapid decline in glu-
cose levels, rather than the absolute degree of hypoglycemia, is
associated with increased arousal from sleep which may lead to
sleep fragmentation.48
Diabetes confers an increased risk of heart failure that is more
in women compared to men and more in middle aged compared
to elderly. Heart failure is associated with early and late insomnia,
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relief of pineal hyperglycemia restores melatonin production to
normal. Melatonin disruption may have detrimental effects on
sleep maintenance and lead to abnormal sleep.51
Limitations of the current study include: (a) the small number
of subjects included, (b) the CDC formulated questionnaire used
in the current study is not validated against ESS, PSQI, or
polysomnography which are considered gold standard methods
for assessment of daytime sleepiness, overall sleep quality, and
sleep disordered breathing respectively, however, the purpose of
this study is to globally characterize sleep abnormalities in diabetic
patients rather than assessing specific domains of abnormal sleep
and this questionnaire better serves this purpose and secondly it
has proven to be effective in characterizing sleep abnormalities
on a much larger sample in the study by Plantinga et al. done
on almost 10 thousand American subjects.15
Other limitations include: (c) not using glycated hemoglobin
which assesses long term glycemic control rather than fasting
and prandial glucose which assess short term glycemic state
because laboratory at our institution is not NSGP (National Glyco-
hemoglobin Standardization Program) certified as recommended
by the American diabetes association, in addition, other authors
similarly reported correlations between abnormal sleep and fast-
ing glycemia.19,20,52 Finally, (d) inclusion of overweight subjects
in groups 2 and 4 may have undermined the differences in sleep
related measures between different groups attributable to obesity
despite the fact that BMI differed significantly between obese
groups [1 & 3] and non-obese groups [2 & 4].
In conclusion, obesity, type 2 diabetes mellitus, or their combi-
nation are associated with poor quality and quantity of sleep with
resultant significant daytime dysfunction. Post-prandial glycemic
status and adiposity significantly predicted Sleep latency, and
number of sleep hours at night.
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